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Abstract
Background/Aims: In this retrospective study we aimed to compare the effect of tranexamic 
acid (TXA) vs etamsylate, two hemostatic agents, on hematuria duration in autosomal dominant 
polycystic kidney disease (ADPKD) patients with persistent gross hematuria. Methods: This is 
a retrospective study of 40 patients with ADPKD and macroscopic hematuria. 20 patients 
receiving TXA and snake venom blood clotting enzyme injection were compared with 20 
matched patients receiving etamsylate and snake venom blood clotting enzyme injection. 
The primary outcome was hematuria duration and the secondary outcomes were blood 
transfusion requirements and adverse events. Results: The hematuria duration was shorter 
in the TXA group compared with the etamsylate group (4[3-5] d vs 7[6-10] d, P<0.001). The 
volume of blood transfusion tended to be less in the TXA group than in the etamsylate group 
(300±115 ml vs 486±195 ml, P=0.12), and the number of patients needing a blood transfusion 
also tended to be lower [20% (4/20) vs 35% (7/20), P=0.29]. TXA and etamsylate were equally 
well tolerated and no serious adverse events were observed in both groups. Conclusions: Our 
study indicates that TXA treatment was more effective than etamsylate in stopping bleeding 
in ADPKD patients with persistent gross hematuria.
Q. Yao, M. Wu and J. Zhou contributed equally to this paper and therefore share first authorship. R.P. Wüthrich, 
Y. Ma and C. Mei contributed equally to this paper and therefore share last and correspondence authorship.
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IntroductionAutosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and it is characterized by the gradual expansion of countless renal cysts in bilateral kidneys leading to end stage renal disease (ESRD) [1]. The most common complications in ADPKD include hypertension, cyst hemorrhage, cyst infection, and renal calculi. In many parts of the world including China and the United States, ADPKD is still an untreatable kidney disorder, and only supportive therapies are available to control and reduce complications [2-4].Cyst bleeding is a frequent and sometimes serious complication in ADPKD [5]. If a hemorrhagic cyst is connected to the kidney collecting system, patients may manifest with gross (macroscopic) hematuria. About 42% to more than 50% of ADPKD patients experience at least one episode of gross hematuria [6], and gross hematuria may be the initial diagnostic clue in up to 20% of ADPKD patients [6]. During an episode of gross hematuria, patients develop macroscopic hematuria and abdominal or loin pain. In most instances, gross hematuria is well controlled by conservative treatment such as strict bed rest, use of hemostatic agents and blood transfusions. In severe cases, i.e. when gross hematuria is prolonged for more than one week and still does not cease with conservative medical therapies, patients may need invasive treatment involving renal transcatheter arterial embolization (TAE), and in rare cases nephrectomy.In the past, several approaches have been used to treat persistent gross hematuria in order to avoid prolonged hospitalization and invasive procedures [7-11]. Among these, 
tranexamic acid (TXA), a potent antifibrinolytic agent, is reported to be an effective drug to stop serious gross hematuria in ADPKD patients [9-11]. However, the evidence for 
efficacy of TXA treatment in ADPKD is limited since only 8 ADPKD patients were involved in a prospective uncontrolled study and two other TXA treated ADPKD patients were reported as case studies. Etamsylate is a widely-used hemostatic agent, which displays 
therapeutic benefits in dysfunctional uterine bleeding, periventricular hemorrhage, and surgical or postsurgical capillary bleeding through improving platelet adhesiveness and restoring capillary resistance [12]. We have used etamsylate as a hemostatic agent to stop cystic bleeding in clinical practice in our department. Snake venom blood clotting enzyme is a procoagulant and routinely used as a hemostatic agent in our clinics. It is derived from snake venom which contains a mixture of biologically active substances that interact with the hemostatic system [13].
In the present retrospective study, 40 ADPKD patients with a definite diagnosis of persistent gross hematuria were enrolled. Their clinical data were analyzed in order 
to compare the efficacy and safety of TXA vs etamsylate treatment for persistent gross hematuria in ADPKD.
Study Population and Methods
ParticipantsThis retrospective chart review study was performed using the database of the Nephrology Department of Changzheng Hospital, the Second Military Medical University. We screened for ADPKD patients suffering from gross hematuria as initial symptom on admission and without any invasive intervention including TAE and nephrectomy from January 2010 to July 2015. A total of 370 ADPKD patients with gross hematuria were 
identified (Fig. 1).
Inclusion and exclusion criteria
Every patient had an established diagnosis of ADPKD as defined by the criteria of Pei et al [14]. Patients were selected for the study if they presented with gross hematuria as initial symptom, which lasted for more than one week and were unresponsive to conservative treatment including snake venom blood clotting 
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enzyme. Among them, 220 patients had gross hematuria persisting over one week before admission and 
were unresponsive to conservative treatment (Fig. 1). Patients with the following conditions were excluded: requiring long-term use of anticoagulants or anti-platelet drugs due to various reasons, having received renal replacement therapy (dialysis or kidney transplantation), concurrent renal stone disease, tumors of the urinary system, hydronephrosis, trauma or extra-renal infections. Before or during hospitalization, patients routinely underwent renal magnetic resonance imaging (MRI) or MRI of urinary system (MRU) to rule out tumors of the urinary system or hydronephrosis. In accordance with inclusion criteria described above, 97 
patients were selected for further analysis (Fig. 1). Among these 97 patients, 20 patients who were treated with the TXA [4-(aminomethyl) cyclohexanecarboxylic acid; Wuzhou pharmaceutical company, Guangxi, China] plus snake venom blood clotting enzyme (a mixture of batroxobin and phospholipids dependent coagulation factor X activators, Zhaoke pharmaceutical company, Hefei, China) were designated as the TXA group. The same number of matched patients whose treatment consisted of etamsylate (2,5-dihydroxy-benzene-sulfonate diethylammonium salt, Jiuzhou pharmaceutical company, Anyang, China) and snake venom blood clotting enzyme was chronologically sorted according to the time of admission and named as the etamsylate group. Patients in the etamsylate group were matched with patients in the TXA group with respect to age, sex, serum creatinine, and hemoglobin concentration on admission. This study was approved by the Ethics Committee of Changzheng Hospital.
Medical treatment during hospitalizationPatients in both groups were asked to observe strict bed rest. Erythropoietin (EPO) was used in 
patients with anemia. The dosage of EPO varied from 10,000 U to 18,000 U per week. Some patients received transfusion of red cell suspension. During bleeding, some patients had urinary tract infections as shown by fever development, abdominal or loin pain, or increase in white blood cell count in urine. Patients with concurrent urinary tract infections received antibiotic therapy according to the results of pathogen culture and sensitivity of the drugs. Combined administration of water soluble antibiotic and fat soluble antibiotic were used before the drug sensitivity test. Antibiotics taken in our study mainly included cephalosporins, metronidazole, and quinolones. Upon hospital admission, patients in the TXA group were given intravenous drip of TXA and at the same time also given snake venom blood coagulation enzyme by intramuscular injection (1000 U) once followed by intravenous injection (1000 U) once daily until the disappearance of 
Fig. 1. Flowchart of TXA/etamsylate study in ADPKD patients.
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macroscopic hematuria for 48h. The dosage of TXA was adjusted according to serum creatinine levels in 
patients with impaired renal function: for patients with serum creatinine levels <250 μmol/L, 10 mg/kg intravenously (IV) injection twice daily; for patients with serum creatinine concentrations of 250 to 500 
μmol/L, 10 mg/kg IV injection once daily; for patients with serum creatinine levels >500 μmol/L, 5mg/kg IV injection once daily [15]. Thus most patients in the TXA group were administrated with TXA at the dose 
of 0.5 g via IV injection once or twice daily. Only for patients whose serum creatinine levels >500 μmol/L, the dosage of 0.25 g IV injection once daily was given. Upon admission, patients in the etamsylate group were given an intravenous drip of etamsylate 1000 mg twice daily until the disappearance of macroscopic 
hematuria for 48h. The etamsylate group was also given snake venom blood coagulation enzyme at the same time by intramuscular injection (1000 U) once followed by intravenous injection (1000 U) once daily 
until the disappearance of macroscopic hematuria for 48h.
OutcomesThe primary outcome of our study was hematuria duration. Given that all patients enrolled had suffered 
from gross hematuria over 1 week before admission, hematuria duration was defined as the period from the day on admission to the day when macroscopic hematuria was disappeared. Patients whose microscopic 
hematuria were not stopped by the treatments and needed embolization or nephrectomy were defined as treatment failures, and excluded for hemostatic time calculation. The secondary outcomes included 
blood transfusion volume and rate, change in renal function, change in blood coagulation and fibrinolysis parameters, and adverse events, including treatment failures. We recorded demographics, duration of gross hematuria before admission to our department, ultrasound examination results and clinical biochemistry parameters before and after receiving medical treatment, such as hemoglobin, platelet count, urine red 
blood cell, fibrinolysis parameters (plasma fibrinogen degradation products [FDP], D-Dimer and fibrinogen 
[Fg]) and coagulation parameters (prothrombin time [PT], activated partial thromboplastin time [aPTT]), 
serum creatinine and estimated glomerular filtration rate (eGFR). The eGFR was calculated by the CKD-EPI formula. Once the macroscopic hematuria was stopped, aforementioned parameters were re-examined. In addition, adverse events due to drugs especially TXA were our important observational items.
Statistical AnalysisContinuous variables accorded with normal distribution were expressed as mean ± standard deviation, otherwise were expressed as median [interquartile range (IQR)]. Hematuria duration, which was skewed distributed, was presented as median [IQR]. Categorical variables are expressed as percentages. Clinical and laboratory parameters were compared using a two-sample t-test, Mann-Whitney U test or Chi-squared test, as appropriate. Changes during treatment within each group were analyzed with a paired t-test. All analyses 
were conducted using SPSS Version 21.0 statistical software. A P value < 0.05 was considered significant.
Results
General Characteristics of the Patients at BaselineThe baseline data of the two treatment groups are shown in Table 1. The treatment 
groups were well matched regarding age, sex, systolic and diastolic blood pressure, eGFR, 
and kidney length. Bleeding time before admission did not differ significantly between the 
two groups. Furthermore, the baseline coagulation and fibrinolysis parameters in both groups were also similar (Table 2).
The Primary Outcome of Treatment
The mean time to achieve hemostasis was significantly shorter in the TXA group 
compared with the etamsylate group, amounting to 4[3-5] days vs 7[6-10] days (P<0.001, 
Table 3 and Fig. 2).
The Secondary Outcomes of TreatmentThe volume of blood transfusion in patients in the TXA group was numerically lower 
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compared with the etamsylate group (300±115 ml vs 486±195 ml, P=0.12, Table 3), and the number of patients needing blood transfusions in the TXA group tended to be less than that 
in the etamsylate group [20% (4/20) vs 35% (7/20), P=0.29, Table 3].Table 4 shows the adverse events (AE) that occurred during hospitalization. In the etamsylate group, 1 patient needed nephrectomy of the affected kidney; 2 patients underwent segmental renal arterial embolization of the affected kidney. While in the TXA group, 1 patient underwent nephrectomy, and none underwent embolization of the affected kidney. 
Table 1. Baseline demo-graphics and clinical cha-racteristics of treatment groups
Table 2. Coagulation and 
fibrinolysis parameters within two groups du-ring the treatments
Table 3. Clinical course and related parameters within two groups during the treatments
 Kidney Blood Press Res 2017;42:156-164
DOI: 10.1159/000474961
Published online: April 10, 2017
© 2017 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 161
Yao/Wu/Zhou et al.: TXA Treatment in ADPKD
Thus, the treatment failures in the TXA group tended to be less than in the etamsylate group [5% 
(1/20) vs 15% (3/20), P=0.60]. A similar number of patients developed fever (13 vs 12) or were treated with antibiotics (17 vs 16) in the TXA vs etamsylate groups.
Additional AE: In the TXA group, two patients suffered from dysuria and achieved remission after urethral catheterization. No clot was found during urethral catheterization. Other patients did not have obstructive urinary symptoms. Besides, no other serious adverse events including 
Fig. 2. Hemostatic time after the TXA or etamsylate tre-atments. Of a total of 40 ADPKD patients enrolled in this study, 17 patients in the etamsylate group and 19 patients in the TXA group were analyzed for hemostatic time. And other 4 patients who received embolization or nephrec-tomy were excluded for hemostatic time calculation. The median value of hemostatic time was shown as a horizon-tal line.
Table 4. Adverse events in two groups during the treatments
deep vein thrombosis or neurological abnormalities were observed in both groups.During hospitalization, renal function of patients in both groups remained stable (Table 3). The urine 
red blood cell counts were significantly decreased in both groups after medical 
treatments (Table 3). Levels of plasma 
fibrinogen degradation products 
(FDPs) and D-dimer were significantly decreased after treatment in the TXA group (Table 2). However, this was not observed in the etamsylate group (Table 2). In addition, levels of coagulation parameters (PT, aPTT) 
and fibrinogen were not significantly changed after the treatments in both groups (Table 2).
Discussion
Excessive angiogenesis [16-18] 
and secondary hyperfibrinolysis [19] 
especially local hyperfibrinolysis [7] may account for the development of persistent gross hematuria in 
ADPKD patients. Antifibrinolytic agents are used to treat ADPKD patients with persistent gross hematuria [7-11]. Among them, TXA is a potent antifibrinolytic agent, which exerts 
antifibrinolytic effect through reversibly blocking the binding of plasminogen to fibrin [20].In the present retrospective study, 40 ADPKD patients with persistent gross hematuria receiving TXA or etamsylate treatment were studied retrospectively. We found that TXA 
halted the bleeding more effectively than etamsylate in ADPKD patients. First, the bleeding 
duration of the TXA group was significantly shorter than that of the etamsylate group. 
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Second, the volume of blood transfusion in the TXA group appeared to be reduced compared with that in the etamsylate group, and the blood transfusion rate in the TXA group tended to be lower than that in the etamsylate group, which is consistent with previous reports that use of TXA could reduce blood loss and blood transfusion rate in major surgeries [21-25]. Third, the number of nephrectomies or embolizations was lower in the TXA group.The reason why TXA was more effective than etamsylate to stop persistent gross 
hematuria might be due to the excessive hyperfibrinolysis existing locally in polycystic 
kidneys [7]. In this study we found that the plasma D-dimer and FDPs, two systemic 
fibrinolysis parameters, were significantly decreased in patients of the TXA group, confirming 
that TXA inhibited the hyperfibrinolysis in polycystic kidneys. In our previous report, we 
observed a significantly lower thrombocyte count in ADPKD patients with lower eGFR and higher TKV, implying that advanced ADPKD patients are at high risk for cystic bleeding [26]. 
Thus the increase of thrombocyte number and/or enhancing thrombocyte activity could be important to control cystic bleeding in advanced ADPKD patients. In the current study, the platelet count was increased by etamsylate treatment. Besides, etamsylate is a hemostatic agent working through improving platelet adhesiveness and restoring capillary resistance [12]. However, the less potent effect of etamsylate on persistent gross hematuria in ADPKD was probably due to the reported mild hemostatic effect of this agent and less pathogenic importance of platelets in ADPKD.Intravenous TXA is eliminated entirely through the kidneys and could accumulate 
in patients with chronic renal failure (CRF) [15]. Adverse effects of TXA treatment have been reported in kidney diseases [27-29]. Koo et al. reported a case of acute renal cortical necrosis induced by large dosage of TXA [29]. The dosage of TXA we used in this study was taken according to suggestions recommended by Andersson et al. for TXA treatment in 
CRF [15]. Indeed, no renal damage was observed during the TXA treatment in our study, 
and levels of serum creatinine and eGFR remained relative stable. Among several patients, anemia improved and serum creatinine were even moderately decreased after correction of prerenal hypovolemia. TXA treatment may induce thromboembolic complication and urinary obstruction by clots [30-33]. Hydration and alkalinizing urine therapy can be used to prevent urinary obstruction. We found that only two patients in the TXA group suffered from dysuria and achieved remission after undergoing urethral catheterization. No clot was found during catheterization in this study. In addition, in the TXA group, PT and aPTT were not obvious changed during the treatments suggesting that TXA had no powerful impact on coagulation. Overall, TXA was well tolerated and serious or severe adverse events were rare [34]. The adverse effects of TXA are dose dependent, thus taking the lower effective dosage of TXA could prevent severe adverse events. Therefore, we adjusted the dosage of TXA according to renal function in ADPKD patients in order to achieve the safety.In our study, there were 1 patient from the TXA group and 3 patients from the etamsylate group whose gross hematuria did not achieve remission and received nephrectomy or TAE. Kidney volumes of these patients were rather large and the ultrasonic test showed that the 
longitudinal diameter of these kidneys were all above 240 millimeter. Furthermore, every one of them underwent cystoscopy for several times and showed hemorrhage from the same side every time. The reason why one patient in the TXA group responded poorly to TXA may 
be explained by the extensive angiogenesis and secondary hyperfibrolysis in large kidneys.
ConclusionADPKD patients, who suffer from cyst hemorrhage which is resistant to conservative treatment and hemostatic drugs, TXA with adjusted dosage can achieve hemostasis more effectively than etamsylate. This may result in a lower requirement of blood transfusions and less invasive procedures, protection of renal function and improvement in the quality of life of ADPKD patients.
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There are several limitations in our study: 1) a retrospective study; 2) the small sample size; 3) lack of information on longtime follow up. A multicenter randomized controlled trial (RCT) should now be performed to better clarify the effectiveness and safety of TXA treatment in ADPKD patients with persistent gross hematuria.
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